NRK

Summary

NRK (Nik related kinase, HGNC:25391) is a protein-coding gene on chromosome Xq22.3, encoding Nik-related protein kinase (Q7Z2Y5). May phosphorylate cofilin-1 and induce actin polymerization through this process, during the late stages of embryogenesis.

The mouse ortholog of this gene encodes a protein kinase required for JNK activation. The encoded protein may be involved in the induction of actin polymerization in late embryogenesis.

Source: NCBI Gene 203447 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 307 total
• Phenotypes (HPO): 1
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• MANE Select transcript: NM_198465

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25391
Approved symbol	NRK
Name	Nik related kinase
Location	Xq22.3
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp686A17109
Ensembl gene	ENSG00000123572
Ensembl biotype	protein_coding
OMIM	300791
Entrez	203447

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 nonsense_mediated_decay

ENST00000243300, ENST00000428173, ENST00000536164, ENST00000540278, ENST00000882683, ENST00000882684

RefSeq mRNA: 1 — MANE Select: NM_198465 NM_198465

CCDS: CCDS65305

Canonical transcript exons

ENST00000243300 — 29 exons

Exon	Start	End
ENSE00001611183	105955505	105958610
ENSE00001619702	105888294	105888419
ENSE00001629171	105900618	105900672
ENSE00001629382	105880199	105880255
ENSE00001654467	105895433	105895523
ENSE00001659882	105905265	105905343
ENSE00001686232	105953034	105953173
ENSE00001688932	105893832	105893942
ENSE00001697981	105949575	105949734
ENSE00001713084	105908240	105908303
ENSE00001721889	105945872	105946015
ENSE00001738379	105946315	105946464
ENSE00001743327	105943941	105944041
ENSE00001743504	105881708	105881779
ENSE00001751732	105906414	105906589
ENSE00001765896	105898584	105898714
ENSE00001779479	105939874	105940032
ENSE00001806791	105831054	105831119
ENSE00002122070	105822539	105822902
ENSE00003711572	105917578	105917672
ENSE00003713251	105915730	105915797
ENSE00003713369	105908727	105909882
ENSE00003721886	105923118	105923482
ENSE00003723679	105937439	105937582
ENSE00003726250	105912648	105912755
ENSE00003732833	105924695	105925031
ENSE00003741697	105935170	105935325
ENSE00003742642	105934258	105934444
ENSE00003749873	105921964	105922061

Expression profiles

Bgee: expression breadth ubiquitous, 166 present calls, max score 98.84.

FANTOM5 (CAGE): breadth broad, TPM avg 5.1157 / max 770.6052, expressed in 502 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
197146	3.1734	408
197145	0.7925	240
197147	0.5210	146
197148	0.2474	116
197143	0.2333	78
197144	0.0746	27
197149	0.0377	4
197150	0.0359	4

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibia	UBERON:0000979	98.84	gold quality
adrenal tissue	UBERON:0018303	98.65	gold quality
placenta	UBERON:0001987	94.57	gold quality
cartilage tissue	UBERON:0002418	91.14	gold quality
kidney epithelium	UBERON:0004819	87.99	gold quality
ovary	UBERON:0000992	87.67	gold quality
left ovary	UBERON:0002119	87.17	gold quality
cauda epididymis	UBERON:0004360	86.91	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.72	gold quality
parietal pleura	UBERON:0002400	86.59	gold quality
germinal epithelium of ovary	UBERON:0001304	85.88	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.64	gold quality
right ovary	UBERON:0002118	84.58	gold quality
right adrenal gland cortex	UBERON:0035827	84.29	gold quality
adrenal cortex	UBERON:0001235	84.16	gold quality
left adrenal gland cortex	UBERON:0035825	83.73	gold quality
adrenal gland	UBERON:0002369	83.55	gold quality
left adrenal gland	UBERON:0001234	83.02	gold quality
right adrenal gland	UBERON:0001233	82.77	gold quality
buccal mucosa cell	CL:0002336	81.57	gold quality
corpus epididymis	UBERON:0004359	81.50	gold quality
cerebellar vermis	UBERON:0004720	81.20	gold quality
caput epididymis	UBERON:0004358	81.19	gold quality
renal medulla	UBERON:0000362	81.08	gold quality
gall bladder	UBERON:0002110	80.67	gold quality
calcaneal tendon	UBERON:0003701	78.52	gold quality
metanephros	UBERON:0000081	77.70	gold quality
kidney	UBERON:0002113	75.57	gold quality
tendon	UBERON:0000043	75.12	gold quality
tendon of biceps brachii	UBERON:0008188	73.57	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	45.47
E-MTAB-10042	yes	8.40
E-CURD-112	yes	6.57
E-ANND-3	yes	6.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

221 targeting NRK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-32-5P	99.98	75.21	1964

Literature-anchored findings (GeneRIF, showing 4)

• The results suggest that Nrk suppresses the excessive proliferation of mammary epithelial cells during pregnancy, and the impairment of this regulatory system leads to frequent occurrence of breast tumor in Nrk mutant mice. (PMID:27634343)
• Nik-related kinase is targeted for proteasomal degradation by the chaperone-dependent ubiquitin ligase CHIP. (PMID:32162334)
• Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment. (PMID:33387038)
• Identification and functional activity of Nik related kinase (NRK) in benign hyperplastic prostate. (PMID:38459501)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nrk	ENSMUSG00000052854
rattus_norvegicus	Nrk	ENSRNOG00000008880

Paralogs (35): MAP3K14 (ENSG00000006062), MAP4K3 (ENSG00000011566), MAP4K5 (ENSG00000012983), MAP2K3 (ENSG00000034152), SLK (ENSG00000065613), MAP4K4 (ENSG00000071054), STK10 (ENSG00000072786), PAK3 (ENSG00000077264), STRADB (ENSG00000082146), MAP3K1 (ENSG00000095015), STK4 (ENSG00000101109), PAK5 (ENSG00000101349), STK24 (ENSG00000102572), STK3 (ENSG00000104375), MAP4K1 (ENSG00000104814), MAP3K8 (ENSG00000107968), MAP2K6 (ENSG00000108984), NEK4 (ENSG00000114904), STK25 (ENSG00000115694), PAK4 (ENSG00000130669), STK26 (ENSG00000134602), TAOK3 (ENSG00000135090), PAK6 (ENSG00000137843), MINK1 (ENSG00000141503), PAK1 (ENSG00000149269), TAOK2 (ENSG00000149930), TNIK (ENSG00000154310), TAOK1 (ENSG00000160551), MAP4K2 (ENSG00000168067), OXSR1 (ENSG00000172939), MAP3K19 (ENSG00000176601), PAK2 (ENSG00000180370), SBK2 (ENSG00000187550), STK39 (ENSG00000198648), STRADA (ENSG00000266173)

Protein

Protein identifiers

Nik-related protein kinase — Q7Z2Y5 (reviewed: Q7Z2Y5)

All UniProt accessions (3): B7Z1I7, Q7Z2Y5, F5H049

UniProt curated annotations — full annotation on UniProt →

Function. May phosphorylate cofilin-1 and induce actin polymerization through this process, during the late stages of embryogenesis. Involved in the TNF-induced signaling pathway.

Similarity. Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. STE20 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q7Z2Y5-1	1	yes
Q7Z2Y5-2	2
Q7Z2Y5-3	3

RefSeq proteins (1): NP_940867* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001180	CNH_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR051700	STE20_Ser-Thr_kinase	Family

Pfam: PF00069, PF00780

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (51 total): sequence variant 15, compositionally biased region 12, modified residue 5, sequence conflict 5, splice variant 4, region of interest 3, domain 2, binding site 2, chain 1, active site 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z2Y5-F1	47.87	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 177 (proton acceptor)

Ligand- & substrate-binding residues (2): 31–39; 54

Post-translational modifications (5): 852, 855, 1027, 1031, 1034

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 176 (showing top): RNGTGGGC_UNKNOWN, ACTACCT_MIR196A_MIR196B, E2F4DP1_01, GCANCTGNY_MYOD_Q6, ATACCTC_MIR202, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, AACYNNNNTTCCS_UNKNOWN, HNF1_Q6, GGGTGGRR_PAX4_03, AATGGAG_MIR136, CAGCTG_AP4_Q5, E2F1DP1_01, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, E2F1DP2_01, PID_TNF_PATHWAY

GO Biological Process (2): positive regulation of JNK cascade (GO:0046330), protein phosphorylation (GO:0006468)

GO Molecular Function (7): protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
JNK cascade	1
positive regulation of MAPK cascade	1
regulation of JNK cascade	1
phosphorylation	1
protein modification process	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

230 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NRK	KRTAP7-1	Q8IUC3	530
NRK	KLHDC10	Q6PID8	495
NRK	RRAGC	Q9HB90	393
NRK	FGL2	Q14314	349
NRK	C9orf152	Q5JTZ5	328
NRK	MBP	P02686	312
NRK	RMDN2	Q96LZ7	305
NRK	AKAP14	Q86UN6	305
NRK	MYBPC1	Q00872	278
NRK	AKNAD1	Q5T1N1	262
NRK	RGS5	O15539	254
NRK	SH3RF2	Q8TEC5	253
NRK	RUFY3	Q7L099	250
NRK	PLAC1	Q9HBJ0	237
NRK	PAK1IP1	Q9NWT1	228

IntAct

3 interactions, top by confidence:

A	B	Type	Score
RYBP	PIPSL	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): NRK (Proximity Label-MS), NRK (Affinity Capture-MS), NRK (Positive Genetic), UHRF1BP1 (Affinity Capture-MS), NRK (Affinity Capture-MS), PLCB3 (Cross-Linking-MS (XL-MS)), NRK (Cross-Linking-MS (XL-MS)), NRK (Proximity Label-MS), NRK (Proximity Label-MS), NRK (Proximity Label-MS)

ESM2 similar proteins: A0JPK3, A1YFX5, A2RQG7, A7KBS4, F4JUI3, G3X9G7, O49498, P03131, P04605, P04614, P05909, P0C1K0, P11332, P12453, P18098, P24109, P35965, P98182, Q09424, Q0VCB0, Q19203, Q2YDJ5, Q3UZB0, Q567C6, Q5BI31, Q5EXX3, Q5M948, Q62396, Q6AXY9, Q6PB60, Q6PI77, Q71HP2, Q74124, Q7JUR5, Q7Z142, Q7Z2Y5, Q80YD3, Q86UQ0, Q8C0P7, Q8C6P8

Diamond homologs: A4K2M3, A4K2P5, A4K2Q5, A4K2S1, A4K2T0, A4K2W5, A4K2Y1, A8XJW8, B0LT89, B7ZR30, E1BK52, E9PTG8, F1LP90, F1NBT0, H2L099, O00506, O08815, O14047, O14305, O24527, O54748, O54988, O55092, O55098, O61122, O61125, O88664, O94804, O95819, P46549, P50527, P70218, P83510, P97820, Q0IHQ8, Q0KHQ5, Q12851, Q13043, Q13188, Q1EG27

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
STUB1	“down-regulates quantity by destabilization”	NRK	polyubiquitination

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — LUSC.

Clinical variants and AI predictions

ClinVar

307 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	162
Likely benign	16
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

4249 predictions. Top by Δscore:

Variant	Effect	Δscore
X:105831048:TTGCA:T	acceptor_loss	1.0000
X:105831049:TGCA:T	acceptor_loss	1.0000
X:105831050:GCAG:G	acceptor_loss	1.0000
X:105831051:CAG:C	acceptor_loss	1.0000
X:105831052:A:AG	acceptor_gain	1.0000
X:105831052:A:AT	acceptor_loss	1.0000
X:105831052:AG:A	acceptor_gain	1.0000
X:105831053:G:GA	acceptor_gain	1.0000
X:105831053:GG:G	acceptor_gain	1.0000
X:105831053:GGATC:G	acceptor_gain	1.0000
X:105831116:TTTGG:T	donor_loss	1.0000
X:105831117:TTGG:T	donor_loss	1.0000
X:105831118:TGGT:T	donor_loss	1.0000
X:105831119:GGTA:G	donor_loss	1.0000
X:105831120:G:GG	donor_gain	1.0000
X:105893818:T:A	acceptor_gain	1.0000
X:105893827:TGCAG:T	acceptor_loss	1.0000
X:105893828:GCAGA:G	acceptor_loss	1.0000
X:105893829:CA:C	acceptor_loss	1.0000
X:105893830:A:AG	acceptor_gain	1.0000
X:105893830:A:AT	acceptor_loss	1.0000
X:105893830:AGAT:A	acceptor_gain	1.0000
X:105893831:G:GG	acceptor_gain	1.0000
X:105893831:GATG:G	acceptor_gain	1.0000
X:105893939:TCAGG:T	donor_loss	1.0000
X:105893940:CAGGT:C	donor_loss	1.0000
X:105893941:AGGT:A	donor_loss	1.0000
X:105893942:GGTG:G	donor_loss	1.0000
X:105893943:G:GG	donor_gain	1.0000
X:105893944:T:G	donor_loss	1.0000

AlphaMissense

10363 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:105895473:A:C	D177A	0.998
X:105895473:A:T	D177V	0.998
X:105898587:A:T	D195V	0.998
X:105898637:T:C	F212L	0.998
X:105898639:C:A	F212L	0.998
X:105898639:C:G	F212L	0.998
X:105900627:T:A	W241R	0.998
X:105900627:T:C	W241R	0.998
X:105888417:T:A	W126R	0.997
X:105888417:T:C	W126R	0.997
X:105898589:T:C	F196L	0.997
X:105898591:T:A	F196L	0.997
X:105898591:T:G	F196L	0.997
X:105898643:G:T	G214W	0.997
X:105898655:T:A	W218R	0.997
X:105898655:T:C	W218R	0.997
X:105937472:T:C	L1230P	0.997
X:105937568:T:C	L1262P	0.997
X:105888322:T:C	L94P	0.996
X:105895479:A:T	K179I	0.996
X:105898644:G:A	G214E	0.996
X:105888331:T:C	L97P	0.995
X:105895474:C:A	D177E	0.995
X:105895474:C:G	D177E	0.995
X:105898584:T:A	V194D	0.995
X:105898586:G:C	D195H	0.995
X:105898587:A:C	D195A	0.995
X:105898588:T:A	D195E	0.995
X:105898588:T:G	D195E	0.995
X:105898638:T:C	F212S	0.995

dbSNP variants (sampled 300 via entrez): RS1000065932 (X:105916525 A>G), RS1000142081 (X:105938762 T>G), RS1000175455 (X:105937341 T>A), RS1000203694 (X:105832281 G>C), RS1000204400 (X:105869642 C>A,T), RS1000211098 (X:105896762 G>A), RS1000275227 (X:105907326 A>G), RS1000301794 (X:105877747 C>A), RS1000336904 (X:105927382 T>C), RS1000337517 (X:105887753 A>G), RS1000364295 (X:105954842 G>T), RS1000372485 (X:105887280 A>T), RS1000372572 (X:105953658 C>T), RS1000384376 (X:105899907 G>A), RS1000407564 (X:105867734 T>C)

Disease associations

OMIM: gene MIM:300791 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST009391_1039	Metabolite levels	1.000000e-20
GCST009391_1041	Metabolite levels	5.000000e-12
GCST009391_1047	Metabolite levels	1.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — MSN subfamily

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, increases methylation	6
bisphenol A	affects cotreatment, decreases methylation, decreases expression	2
entinostat	increases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression	2
Benzo(a)pyrene	affects methylation, increases mutagenesis	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
geldanamycin	increases expression	1
trichostatin A	increases expression	1
sodium arsenite	increases abundance, increases expression, affects cotreatment	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	increases expression	1
mercuric bromide	affects cotreatment, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Panobinostat	affects cotreatment, increases expression	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Nickel	decreases expression	1
Oxygen	increases expression	1
Potassium Dichromate	increases expression	1
Tretinoin	increases expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms